Comparative Pharmacology
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus FLOVENT DISKUS 250.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ADVAIR DISKUS 100 50 versus FLOVENT DISKUS 250.
ADVAIR DISKUS 100/50 vs FLOVENT DISKUS 250
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid that exerts anti-inflammatory effects by binding to glucocorticoid receptors, thereby inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppressing cytokine production. Salmeterol is a long-acting beta2-adrenergic agonist (LABA) that stimulates adenyl cyclase, increasing cAMP levels, leading to bronchodilation and inhibition of mast cell mediator release.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
One inhalation (100 mcg fluticasone propionate and 50 mcg salmeterol) twice daily, approximately 12 hours apart, via oral inhalation.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
None Documented
None Documented
Fluticasone propionate: terminal half-life approximately 8 hours (range 4-12 hours) after inhalation; clinical context: supports twice-daily dosing. Salmeterol: terminal half-life approximately 5.5 hours (range 3-10 hours) after inhalation; clinical context: supports twice-daily dosing.
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
Fluticasone propionate: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (~5% unchanged), fecal elimination of parent drug and metabolites. Salmeterol: primarily hepatic metabolism (CYP3A4), renal excretion of metabolites (about 25% of dose), fecal elimination.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Category C
Category C
Corticosteroid/LABA Combination
Corticosteroid